|
US3798209A
(en)
|
1971-06-01 |
1974-03-19 |
Icn Pharmaceuticals |
1,2,4-triazole nucleosides
|
|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
|
US4797286A
(en)
|
1985-11-12 |
1989-01-10 |
Eli Lilly And Company |
Orally administerable sustained release pharmaceutical formulations
|
|
GB8719367D0
(en)
|
1987-08-15 |
1987-09-23 |
Wellcome Found |
Therapeutic compounds
|
|
US5705363A
(en)
|
1989-03-02 |
1998-01-06 |
The Women's Research Institute |
Recombinant production of human interferon τ polypeptides and nucleic acids
|
|
US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
|
DE69132332T2
(de)
|
1990-04-06 |
2000-11-30 |
Genelabs Technologies, Inc. |
Hepatitis c-virus-epitope
|
|
US5372808A
(en)
|
1990-10-17 |
1994-12-13 |
Amgen Inc. |
Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
|
|
US5595732A
(en)
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
|
TW224053B
(https=)
|
1991-09-13 |
1994-05-21 |
Paul B Chretien |
|
|
US5676942A
(en)
|
1992-02-10 |
1997-10-14 |
Interferon Sciences, Inc. |
Composition containing human alpha interferon species proteins and method for use thereof
|
|
US5610054A
(en)
|
1992-05-14 |
1997-03-11 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecule targeted against Hepatitis C virus
|
|
GB9226729D0
(en)
|
1992-12-22 |
1993-02-17 |
Wellcome Found |
Therapeutic combination
|
|
US5496546A
(en)
|
1993-02-24 |
1996-03-05 |
Jui H. Wang |
Compositions and methods of application of reactive antiviral polyadenylic acid derivatives
|
|
US5846964A
(en)
|
1993-07-19 |
1998-12-08 |
Tokyo Tanabe Company Limited |
Hepatitis C virus proliferation inhibitor
|
|
US5433951A
(en)
|
1993-10-13 |
1995-07-18 |
Bristol-Myers Squibb Company |
Sustained release formulation containing captopril and method
|
|
ATE214940T1
(de)
|
1993-11-10 |
2002-04-15 |
Enzon Inc |
Verbesserte interferon-polymerkonjugate
|
|
US5951974A
(en)
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
|
DE4415539C2
(de)
|
1994-05-03 |
1996-08-01 |
Osama Dr Dr Med Omer |
Pflanzen mit virustatischer und antiviraler Wirkung
|
|
DE4432623A1
(de)
|
1994-09-14 |
1996-03-21 |
Huels Chemische Werke Ag |
Verfahren zur Bleichung von wäßrigen Tensidlösungen
|
|
US5738846A
(en)
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
|
US5783846A
(en)
*
|
1995-09-22 |
1998-07-21 |
Hughes Electronics Corporation |
Digital circuit with transistor geometry and channel stops providing camouflage against reverse engineering
|
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
|
US5980884A
(en)
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
|
AU2064297A
(en)
|
1996-02-29 |
1997-09-16 |
Immusol, Inc |
Hepatitis c virus ribozymes
|
|
US5633388A
(en)
|
1996-03-29 |
1997-05-27 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
|
US5830905A
(en)
|
1996-03-29 |
1998-11-03 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
|
US5990276A
(en)
|
1996-05-10 |
1999-11-23 |
Schering Corporation |
Synthetic inhibitors of hepatitis C virus NS3 protease
|
|
GB9609932D0
(en)
|
1996-05-13 |
1996-07-17 |
Hoffmann La Roche |
Use of IL-12 and IFN alpha for the treatment of infectious diseases
|
|
US5891874A
(en)
|
1996-06-05 |
1999-04-06 |
Eli Lilly And Company |
Anti-viral compound
|
|
US5837257A
(en)
|
1996-07-09 |
1998-11-17 |
Sage R&D |
Use of plant extracts for treatment of HIV, HCV and HBV infections
|
|
JP3927630B2
(ja)
|
1996-09-27 |
2007-06-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウイルス感染症の予防・治療剤
|
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
|
KR100509388B1
(ko)
|
1996-10-18 |
2005-08-23 |
버텍스 파마슈티칼스 인코포레이티드 |
세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
|
|
GB9623908D0
(en)
|
1996-11-18 |
1997-01-08 |
Hoffmann La Roche |
Amino acid derivatives
|
|
US6004933A
(en)
|
1997-04-25 |
1999-12-21 |
Cortech Inc. |
Cysteine protease inhibitors
|
|
KR100630506B1
(ko)
|
1997-06-30 |
2006-09-29 |
메르츠 파마 게엠베하 운트 코. 카가아 |
Ｎｍｄａ 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물, 이를 함유하는 제약학적 조성물 및 이것으로 치료하는 방법
|
|
ES2234144T3
(es)
|
1997-08-11 |
2005-06-16 |
Boehringer Ingelheim (Canada) Ltd. |
Analogos de peptidos inhibidores de la hepatitis c.
|
|
ES2186660T3
(es)
|
1997-09-21 |
2003-05-16 |
Schering Corp |
Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
|
|
US5981709A
(en)
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
|
US6350458B1
(en)
|
1998-02-10 |
2002-02-26 |
Generex Pharmaceuticals Incorporated |
Mixed micellar drug deliver system and method of preparation
|
|
WO1999043691A1
(en)
|
1998-02-25 |
1999-09-02 |
Emory University |
2'-fluoronucleosides
|
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
|
AU766597B2
(en)
|
1998-05-15 |
2003-10-16 |
Schering Corporation |
Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
|
|
DK1087778T3
(da)
|
1998-06-08 |
2005-12-19 |
Hoffmann La Roche |
Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
|
|
US6171615B1
(en)
|
1998-07-06 |
2001-01-09 |
Gattefoss{acute over (e)} |
Sustained release theophylline formulations, excipient systems and methods of production
|
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
|
PT2415776T
(pt)
|
1998-08-10 |
2016-07-07 |
Novartis Ag |
Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
|
|
WO2000037110A2
(en)
|
1998-12-18 |
2000-06-29 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction hcv combination therapy
|
|
US6566365B1
(en)
|
1999-11-04 |
2003-05-20 |
Biochem Pharma Inc. |
Method for the treatment of Flaviviridea viral infection using nucleoside analogues
|
|
KR20030005197A
(ko)
|
2000-02-18 |
2003-01-17 |
샤이어 바이오켐 인코포레이티드 |
뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법
|
|
EP1964569A3
(en)
|
2000-04-13 |
2009-07-22 |
Pharmasset, Inc. |
3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
|
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
EP1736478B1
(en)
|
2000-05-26 |
2015-07-22 |
IDENIX Pharmaceuticals, Inc. |
Methods and compositions for treating flaviviruses and pestiviruses
|
|
MY141594A
(en)
|
2000-06-15 |
2010-05-14 |
Novirio Pharmaceuticals Ltd |
3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
|
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
|
KR20030081297A
(ko)
|
2000-07-21 |
2003-10-17 |
쉐링 코포레이션 |
Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
|
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
|
CA2418199A1
(en)
|
2000-07-21 |
2002-01-31 |
Corvas International, Inc. |
Peptides as ns3-serine protease inhibitors of hepatitis c virus
|
|
US20030008841A1
(en)
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
|
WO2002032920A2
(en)
|
2000-10-18 |
2002-04-25 |
Pharmasset Limited |
Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
|
|
AU2002213343A1
(en)
|
2000-10-18 |
2002-04-29 |
Schering Corporation |
Ribavirin-pegylated interferon alfa HCV combination therapy
|
|
DE60119968T2
(de)
|
2000-11-20 |
2007-01-18 |
Bristol-Myers Squibb Co. |
Hepatitis c tripeptid inhibitoren
|
|
KR20030091946A
(ko)
|
2000-12-12 |
2003-12-03 |
쉐링 코포레이션 |
Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 디아릴 펩티드
|
|
AU2002230764A1
(en)
|
2000-12-13 |
2002-06-24 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
|
|
AU2002230763A1
(en)
|
2000-12-13 |
2008-01-03 |
Bristol-Myers Squibb Pharma Company |
Inhibitors of hepatitis c virus ns3 protease
|
|
WO2002048165A2
(en)
|
2000-12-15 |
2002-06-20 |
Pharmasset Ltd. |
Antiviral agents for treatment of flaviviridae infections
|
|
SK286630B6
(sk)
|
2001-01-22 |
2009-02-05 |
Merck & Co., Inc. |
Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
|
|
US6825201B2
(en)
|
2001-04-25 |
2004-11-30 |
Bristol-Myers Squibb Company |
Indole, azaindole and related heterocyclic amidopiperazine derivatives
|
|
WO2003024461A1
(en)
|
2001-09-20 |
2003-03-27 |
Schering Corporation |
Hcv combination therapy
|
|
ITMI20021399A1
(it)
|
2002-06-25 |
2003-12-29 |
Nicox Sa |
Inibitori della cicloossigenasi 2
|
|
TW200500375A
(en)
|
2002-06-28 |
2005-01-01 |
Idenix Cayman Ltd |
Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
|
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
|
CN1678326A
(zh)
|
2002-06-28 |
2005-10-05 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
|
|
JP2006500355A
(ja)
|
2002-08-07 |
2006-01-05 |
イデニクス（ケイマン）リミテツド |
Ｈｉｖ治療用の置換フェニルインドール類
|
|
BRPI0515344A
(pt)
|
2004-09-17 |
2008-07-15 |
Idenix Pharmaceuticals Inc |
composto, composição farmacêutica, e, usos de uma quantidade eficaz de um composto 3-fosfoindol ou sal, pró-droga, estereoisÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo e de uma quantidade de tratamento eficaz anti-hiv de um composto de 3-fosfoindol ou sal, pró-droga, estereo-isÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo
|
|
AU2006294449A1
(en)
|
2005-09-29 |
2007-04-05 |
Repros Therapeutics Inc. |
Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
|
|
JP2010504978A
(ja)
*
|
2006-09-29 |
2010-02-18 |
アイデニクス ファーマシューティカルズ，インコーポレーテッド |
Ｈｉｖ阻害剤としての鏡像異性的に純粋なホスホインドール
|